Biological E seeks EUA for its Corbevax vaccine

Biological E has sought emergency use authorisation from India’s drug regulator for its COVID-19 vaccine Corbevax for the 12 to 18 years age group, official sources said on Sunday. The Drugs Controller General Of India (DCGI) has already approved Corbevax, which is India’s first indigenously developed RBD protein sub-unit vaccineContinue Reading

Indian bankers collect bumper fees from record $18 billion in IPOs

By Administrator_India Capital Sands The US economy grew solidly in the second quarter (Q2), pulling the level of gross domestic product (GDP) above its pre-pandemic peak, as massive government aid and vaccinations against Covid-19 fueled spending on goods and travel-related services. GDP, the broadest measure of economic output, grew 1.6 per cent inContinue Reading

By Administrator_ India Capital Sands Ahmedabad-based pharma major Cadila Healthcare (Zydus Cadila) is planning to start clinical trials on children aged 5 years and above soon for its DNA-plasmid technology-based Covid-19 vaccine, claimed a senior official. Meanwhile, the company is awaiting approval from the Drugs Controller General of India (DCGI)Continue Reading